ketamine + org 25935

Ketamine is a dissociative anesthetic and N-methyl-D-aspartate (NMDA) receptor antagonist used primarily for anesthesia and increasingly for off-label treatment of depression and other psychiatric conditions. It was first discovered by Parke-Davis (now Pfizer) in the 1960s and is FDA-approved as an anesthetic agent. ORG-25935 (also known as SCH 900435) is a synthetic small molecule developed by Organon International that acts as a selective inhibitor of the glycine transporter GlyT1. ORG-25935 has been studied mainly for its antipsychotic properties; in human trials, it was shown to reduce psychosis-like symptoms induced by ketamine administration but did not show significant benefit over placebo in clinical trials for alcohol dependence or schizophrenia negative symptoms. The combination "ketamine + org 25935" refers to research settings where ORG‑25935 is administered to counteract or study the effects of ketamine-induced NMDA receptor antagonism[1][2][3][5].

Other names

ketamine(6-methoxy-1-phenyl-1,2,3,4-tetrahydronaphthalen-2-ylmethyl) amino-methylcarboxylic acid hydrochloride